00:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
11:30 , Jul 9, 2019 |  BioCentury  |  Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor. The financing,...
23:29 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

DISEASE CATEGORY: Endocrine/metabolic; transplant INDICATION: Diabetes; islet cell transplant Inhibition of PTP-1B in pancreatic islet cell grafts could help improve outcomes in Type I diabetes. In a mouse model of Type I diabetes, knockout of...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
21:57 , Jun 14, 2019 |  BC Extra  |  Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells   The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in...
16:57 , Mar 22, 2019 |  BC Week In Review  |  Financial News

Spinal cord injury company NervGen raises $10M IPO

NervGen Pharma raised $10 million in an IPO on TSX Ventures on March 13. It plans to submit an IND late this year for lead candidate, NVG-291, to treat spinal cord injury and peripheral nerve...
01:25 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Cell culture and worm studies suggest the PTP-1B inhibitor trodusquemine could help treat AD. In human cells cultured with β amyloid 42 (Aβ 42 ), trodusquemine decreased the formation of Aβ...
00:00 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Myelomonocytic leukemia; B cell lymphoma; lung cancer In vitro , cell culture and patient sample studies identified a SHP-2 inhibitor that could help treat myelomonocytic leukemia, B cell lymphoma and lung cancer. In silico...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
20:32 , Oct 31, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The numbers of circulating hybrid leukocyte-epithelial cells expressing PTPRC and creatine kinase could help predict survival in pancreatic cancer. In 18 patients, high numbers of the hybrid cells expressing PTPRC and creatine...